Clinical trial
A Phase III Open-label Randomised Study, to Evaluate the Immunogenicity and Safety of the Concomitant Administration of V419 (PR5I) Given at 2, 3 and 4 Months of Age With Two Types of Meningococcal Serogroup C Conjugate (MCC) Vaccines Given at 3 and 4 Months of Age, and Followed by the Administration at 12 Months of Age of a Combined Haemophilus Influenzae Type b-MCC Vaccine
NCT01553279 is registered in ClinicalTrials.gov with MCM Vaccines B.V. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Open-label Randomised Study, to Evaluate the Immunogenicity and Safety of the Concomitant Administration of V419 (PR5I) Given at 2, 3 and 4 Months of Age With Two Types of Meningococcal Serogroup C Conjugate (MCC) Vaccines Given at 3 and 4 Months of Age, and Followed by the Administration at 12 Months of Age of a Combined Haemophilus Influenzae Type b-MCC Vaccine
- Lead sponsor
- MCM Vaccines B.V.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 30, 2012
- Completion date
- September 27, 2013
- Enrollment
- 284 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
bacterial infections, neisseria meningitidis, virus diseases